Scott M. Coiante's Insider Trades & SAST Disclosures
Scott M. Coiante's most recent trade in Lexicon Pharmaceuticals Inc was a trade of 721,070 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Scott M. Coiante.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 721,070 | 721,070 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 480,710 | 480,710 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 230,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
| Aprea Therapeutics Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 89,200 | 89,200 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 60,800 | 145,065 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Scott M. Coiante | Director, SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 03 Jun 2022 | 35,284 | 84,265 (0%) | 0% | 0.8 | 28,404 | Common Stock |
| Aprea Therapeutics Inc | Scott M. Coiante | Director, SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 185,900 | 185,900 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Scott M. Coiante | Director, SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 42,900 | 119,549 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Scott M. Coiante | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.74 per share. | 25 Feb 2022 | 14,817 | 76,649 (0%) | 0% | 1.7 | 25,782 | Common Stock |
| Aprea Therapeutics Inc | Scott M. Coiante | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.98 per share. | 25 Aug 2021 | 7,534 | 91,466 (0%) | 0% | 4.0 | 29,985 | Common Stock |
| Aprea Therapeutics Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 143,000 | 143,000 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 63,500 | 99,000 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 33,000 | 35,500 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2020 | 55,000 | 55,000 | - | - | Stock Option (right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges